bioAffinity Technologies, Inc. (BIAF)
BIAF moved a median of 0.00% 30 minutes after news, and 0.00% by the close. How BIAF actually reacts to news — the realized, point-in-time move the market made, measured across 389 labeled events over the last three years with zero look-ahead.
BIAF’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | 0.00% | 46% | 360 |
| 30-min | 0.00% | 50% | 376 |
| 60-min | +0.07% | 51% | 377 |
| to close | 0.00% | 48% | 386 |
| Middle 50% of BIAF reactions | -2.35% to +1.94% |
|---|---|
| Median reaction (30-min) | 0.00% |
| Measured reactions | 389 |
Half of all bioAffinity Technologies, Inc. news events land between -2.35% and +1.94% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
Email me when BIAF moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BIAF's baseline. Nothing else.
Recent BIAF events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| bioAffinity Technologies to Present New Perspectives on CyPath® Lung’s Use for Cancer Risk Assessment at CHEST 2026 | Press release | Business Wire | -0.65% | +14.12% | |
| Form 8-K bioAffinity Technologies For: Oct 15 | SEC filing · Form 8-K | SEC EDGAR | +1.10% | +16.13% | |
| bioAffinity Technologies to Present Positive Research Data in Development of Its New Test Measuring Asthma and COPD-Related Lung Inflammation and Drug-Related Receptors at CHEST 2026 | Press release | Business Wire | -1.99% | +2.98% | |
| Form 8-K bioAffinity Technologies For: Oct 13 | SEC filing · Form 8-K | SEC EDGAR | -1.99% | +2.98% | |
| Form PRER14A bioAffinity Technologies | SEC filing · Form PRER14A | SEC EDGAR | -1.99% | +2.98% | |
| bioAffinity Technologies, Inc. Announces Closing of $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules | Press release | Business Wire | +0.03% | -4.35% | |
| Form 8-K bioAffinity Technologies For: Oct 08 | SEC filing · Form 8-K | SEC EDGAR | -2.95% | -17.89% | |
| WallachBeth Capital Announces Closing of bioAffinity Technologies $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules | Press release | PR Newswire | -0.62% | -2.78% | |
| bioAffinity Technologies Announces Notification of Japanese Patent Allowance Covering Noninvasive CyPath® Lung and AI-Built Algorithm | Press release | Business Wire | +4.09% | -11.18% | |
| bioAffinity Technologies, Inc. Announces Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules | Press release | Business Wire | -6.22% | -25.40% | |
| Form 8-K bioAffinity Technologies For: Oct 08 | SEC filing · Form 8-K | SEC EDGAR | +4.09% | -11.18% | |
| WallachBeth Capital Announces bioAffinity Technologies Approximately $4 Million Registered Direct Financing of Common Stock and Concurrent Private Placement Priced At-The-Market Under Nasdaq Rules | Press release | PR Newswire | -1.43% | -10.48% | |
| bioAffinity Technologies Reports Over 100% Growth in CyPath® Lung Sales Through Third Quarter 2026 | Press release | Business Wire | -2.53% | -7.05% | |
| Form 8-K bioAffinity Technologies For: Oct 06 | SEC filing · Form 8-K | SEC EDGAR | -2.53% | -7.05% | |
| bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL | Press release | Business Wire | +2.90% | +0.00% | |
| Form 8-K bioAffinity Technologies For: Sep 30 | SEC filing · Form 8-K | SEC EDGAR | +2.90% | +0.00% | |
| Form PRE 14A bioAffinity Technologies For: Sep 29 | SEC filing · Form PRE | SEC EDGAR | +0.14% | -5.10% | |
| bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference | Press release | Business Wire | +2.33% | +3.32% | |
| Form 8-K bioAffinity Technologies For: Sep 22 | SEC filing · Form 8-K | SEC EDGAR | +2.33% | +3.32% | |
| bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic | Press release | Business Wire | +2.58% | +25.54% | |
| Form 8-K bioAffinity Technologies For: Sep 17 | SEC filing · Form 8-K | SEC EDGAR | +2.58% | +25.54% | |
| Form 8-K bioAffinity Technologies For: Sep 11 | SEC filing · Form 8-K | SEC EDGAR | -0.50% | -20.18% | |
| bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements | Press release | Business Wire | +4.42% | -3.40% | |
| Form 8-K bioAffinity Technologies For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | +4.42% | -3.40% | |
| Form EFFECT bioAffinity Technologies | SEC filing · Form EFFECT | SEC EDGAR | -13.45% | -15.99% | |
| bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference | Press release | Business Wire | +3.12% | +38.19% | |
| Form 8-K bioAffinity Technologies For: Sep 03 | SEC filing · Form 8-K | SEC EDGAR | +3.12% | +38.19% | |
| Form S-3/A bioAffinity Technologies | SEC filing · Form S-3 | SEC EDGAR | +3.12% | +38.19% | |
| bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors | Press release | Business Wire | +1.05% | -13.29% | |
| Form 8-K bioAffinity Technologies For: Sep 01 | SEC filing · Form 8-K | SEC EDGAR | +20.13% | +29.14% | |
| Form S-3 bioAffinity Technologies | SEC filing · Form S-3 | SEC EDGAR | +1.82% | -1.62% | |
| bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026 | Press release | Business Wire | +14.57% | +9.62% | |
| Form 8-K bioAffinity Technologies For: Aug 20 | SEC filing · Form 8-K | SEC EDGAR | +14.57% | +9.62% | |
| bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung | Press release | Business Wire | -1.72% | -12.61% | |
| Form 8-K bioAffinity Technologies For: Aug 18 | SEC filing · Form 8-K | SEC EDGAR | -1.72% | -12.61% | |
| bioAffinity Technologies Announces Closing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules | Press release | Business Wire | +0.65% | +3.90% | |
| Form 8-K bioAffinity Technologies For: Aug 12 | SEC filing · Form 8-K | SEC EDGAR | -0.10% | -5.54% | |
| WallachBeth Capital Announces Closing of bioAffinity Technologies $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules | Press release | PR Newswire | +0.49% | +3.10% | |
| bioAffinity Technologies Announces Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules | Press release | Business Wire | -1.99% | -15.45% | |
| WallachBeth Capital Announces bioAffinity Technologies Pricing of $4M Private Placement Offering Priced At-the-Market Under Nasdaq Rules | Press release | PR Newswire | -1.15% | -10.96% | |
| bioAffinity Technologies Reports Second Quarter 2026 Results and Continued Strong Commercial Momentum for CyPath® Lung | Press release | Business Wire | -0.47% | -3.77% | |
| Form 10-Q bioAffinity Technologies For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +1.18% | — | |
| Form 8-K bioAffinity Technologies For: Aug 07 | SEC filing · Form 8-K | SEC EDGAR | -0.47% | -3.77% | |
| Form 8-K bioAffinity Technologies For: Jul 30 | SEC filing · Form 8-K | SEC EDGAR | -3.12% | -1.91% | |
| bioAffinity Technologies Publishes New Clinical Framework Addressing Growing Market for Pulmonary Nodule Risk Stratification and Early Lung Cancer Detection Using CyPath® Lung | Press release | Business Wire | +0.32% | +4.41% | |
| Form 8-K bioAffinity Technologies For: Jul 27 | SEC filing · Form 8-K | SEC EDGAR | +0.32% | +4.41% | |
| bioAffinity Technologies and Pictor®, Inc. Partner to Develop and Commercialize bioAffinity’s Diagnostics for Asthma and COPD | Press release | Business Wire | +1.83% | +0.40% | |
| Form 8-K bioAffinity Technologies For: Jul 22 | SEC filing · Form 8-K | SEC EDGAR | +1.83% | +0.40% | |
| bioAffinity Technologies’ Quarterly CyPath® Lung Sales Double to New Record as Commercial Momentum Continues | Press release | Business Wire | -0.54% | +0.00% | |
| Form 8-K bioAffinity Technologies For: Jul 07 | SEC filing · Form 8-K | SEC EDGAR | -0.54% | +0.00% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BIAF section they belong to.
Where else BIAF is measured.
BIAF earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is bioAffinity Technologies, Inc.'s median reaction calculated?
Every labeled BIAF news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 389 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 50% of BIAF's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BIAF's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.